Literature DB >> 9812202

The response-to-retention hypothesis of atherogenesis reinforced.

K J Williams1, I Tabas.   

Abstract

Many lines of evidence indicate that the key initiating event in early atherosclerosis is the subendothelial retention of cholesterol-rich, atherogenic lipoproteins. Once retained, these lipoproteins provoke a cascade of responses that lead to disease in a previously non-lesional artery. We review recent experimental work that has substantially reinforced this hypothesis. Lipoprotein retention has been shown to be a pivotal requirement in the murine model of atherosclerosis: low-density lipoprotein, engineered through site-directed mutagenesis of apolipoprotein-B100 to bind poorly to arterial proteoglycans, causes relatively few lesions in vivo, even during significant hyperlipidemia. In addition, many molecules in the arterial wall that are involved in the retention of atherogenic lipoproteins and in arterial responses to retained material have recently been characterized. Overall, the response-to-retention hypothesis can now be regarded as a central paradigm in our understanding of the pathogenesis of this deadly disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9812202     DOI: 10.1097/00041433-199810000-00012

Source DB:  PubMed          Journal:  Curr Opin Lipidol        ISSN: 0957-9672            Impact factor:   4.776


  79 in total

Review 1.  Regulation and mechanisms of macrophage cholesterol efflux.

Authors:  Alan R Tall; Philippe Costet; Nan Wang
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

2.  Effect of liver total sphingomyelin synthase deficiency on plasma lipid metabolism.

Authors:  Zhiqiang Li; Yeun-Po Chiang; Mulin He; Ke Zhang; Jiao Zheng; Weihua Wu; Jiajia Cai; Yong Chen; Guangzhi Chen; Yunqin Chen; Jibin Dong; Tilla S Worgall; Xian-Cheng Jiang
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2021-02-02       Impact factor: 4.698

3.  Influence of oxidatively modified LDL on monocyte-macrophage differentiation.

Authors:  Achuthan Radhika; Shiney S Jacob; Perumana R Sudhakaran
Journal:  Mol Cell Biochem       Date:  2007-07-28       Impact factor: 3.396

4.  Elevated circulating TGF-β is not the cause of increased atherosclerosis development in biglycan deficient mice.

Authors:  Joel C Thompson; Patricia G Wilson; Alex P Wyllie; Adrian K Wyllie; Lisa R Tannock
Journal:  Atherosclerosis       Date:  2017-11-10       Impact factor: 5.162

Review 5.  Changes in the plasma membrane in metabolic disease: impact of the membrane environment on G protein-coupled receptor structure and function.

Authors:  Aditya J Desai; Laurence J Miller
Journal:  Br J Pharmacol       Date:  2017-08-03       Impact factor: 8.739

6.  Aggregated electronegative low density lipoprotein in human plasma shows a high tendency toward phospholipolysis and particle fusion.

Authors:  Cristina Bancells; Sandra Villegas; Francisco J Blanco; Sonia Benítez; Isaac Gállego; Lorea Beloki; Montserrat Pérez-Cuellar; Jordi Ordóñez-Llanos; José Luis Sánchez-Quesada
Journal:  J Biol Chem       Date:  2010-07-29       Impact factor: 5.157

Review 7.  The UPR in atherosclerosis.

Authors:  Alex X Zhou; Ira Tabas
Journal:  Semin Immunopathol       Date:  2013-04-04       Impact factor: 9.623

8.  Binding to heparin triggers deleterious structural and biochemical changes in human low-density lipoprotein, which are amplified in hyperglycemia.

Authors:  Shobini Jayaraman; Olivia R Chavez; Antonio Pérez; Inka Miñambres; Jose Luis Sánchez-Quesada; Olga Gursky
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2020-04-11       Impact factor: 4.698

9.  Expanded network of inflammatory markers of atherogenesis: where are we now?

Authors:  Seyed Hesameddin Abbasi; Mohammad Ali Boroumand
Journal:  Open Cardiovasc Med J       Date:  2010-02-23

10.  Inflammation, a link between obesity and cardiovascular disease.

Authors:  Zhaoxia Wang; Tomohiro Nakayama
Journal:  Mediators Inflamm       Date:  2010-08-05       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.